查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961180

地中海型貧血治療市場－全球產業規模、佔有率、趨勢、機會、預測：依治療方法、類型、最終用戶、地區和競爭格局分類，2021-2031年

Thalassemia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球地中海貧血治療市場預計將從 2025 年的 9.2381 億美元成長到 2031 年的 14.5622 億美元，複合年成長率為 7.88%。

該領域涵蓋的治療方法包括慢性輸血療法、鐵螯合療法、骨髓移植以及新興的基因療法。成長的主要驅動力是全球遺傳性血液疾病發生率的上升以及基因編輯技術等根治性干預措施的整合。此外，政府支持的篩檢計畫的擴展、創新療法的監管核准以及旨在降低BETA-地中海貧血患者輸血依賴性的強大研發管線的建立，也推動了市場的發展。

市場概覽
預測期 2027-2031
市場規模：2025年 9.2381億美元
市場規模：2031年 1,456,220,000 美元
複合年成長率：2026-2031年 7.88%
成長最快的細分市場 α地中海貧血
最大的市場 北美洲

儘管取得了這些進展，但新治療方法的高昂成本以及與長期輸血通訊協定相關的複雜後勤保障阻礙了其廣泛應用。確保穩定安全的血液供應仍然是許多地區面臨的重大挑戰。例如，國際地中海貧血聯合會預測，到2025年，中低收入國家超過75%的患者將面臨血液短缺。這種資源分配上的差距仍然是全球市場進入和公平分配治療方案的重要障礙。

市場促進因素

基因編輯療法的商業化正在從根本上改變全球地中海貧血治療市場，將治療重點從慢性疾病管理轉向潛在的功能性治癒。這項轉變的驅動力在於，針對輸血依賴型BETA-地中海貧血遺傳根源的高價值體外基因療法核准並投入使用，從而獲得了顯著的市場價值，並在專業醫療機構中佔據了重要地位。例如，Bluebird Bio在2024年11月發布的2024年第三季財報中報告稱，截至目前，該公司已在其商業化產品組合中為57名患者啟動了治療，其中35名患者接受了BETA-地中海貧血治療藥物Zintegro的治療。 Vertex Pharmaceuticals在2024年11月發布的2024年第三季財報中也宣布，其基因編輯療法Casgevy已累計200萬美元的首筆商業收入，進一步印證了該公司在財務上的成熟。

同時，地中海貧血和血紅蛋白疾病在全球範圍內的日益流行，推動了對創新治療方法和支持性護理的強勁需求。隨著診斷能力的提高和人口結構的變化，需要終身照護的患者人數不斷增加，尤其是在遺傳特徵高度集中的地區。根據國際地中海貧血聯盟於2025年1月發布的《全球證據與差距圖譜》報告，全球每年約有30萬名兒童出生時患有血紅蛋白疾病，凸顯了開發可擴展治療方法的迫切性。日益加重的疾病負擔要求醫療保健領域進行大量投資，以確保對鐵螯合療法和輸血基礎設施的基本需求仍然是推動治療量成長的關鍵因素，同時基因療法佔據高階市場。

市場挑戰

新型基因療法的高成本是限制全球地中海貧血治療市場成長的主要阻礙因素。儘管這些先進治療方法有望治癒地中海貧血，但其定價結構給醫療保險公司和報銷體系帶來了沉重的經濟負擔。這種經濟壓力限制了療法的普及，許多私人保險公司和公共衛生計畫難以承擔這些療法所需的巨額前期費用。因此，監管部門的核准與患者實際獲得治療之間的差距正在擴大，限制了新興市場和成熟市場製造商的潛在獲利能力。

這種經濟上的排他性造成了公平獲取治療的巨大障礙，目前的行業價格便印證了這一點。根據國際地中海貧血聯合會2025年的報告，已通過核准採集費用基因編輯療法的平均費用將超過每位患者210萬美元。如此高昂的價格障礙實際上使得大多數目標患者無法獲得根治性治療，從而減緩了整體市場成長，並將盈利的商業性機會限制在富裕階層或享受高額醫療補貼的少數群體中。

市場趨勢

由於紅血球成熟促進劑的應用日益廣泛，市場結構正在改變。這些藥物能夠改善紅血球生成，並顯著降低輸血依賴性。這些生物製藥針對紅血球分化的後期階段，為那些無法獲得或合格接受根治性基因編輯療法的患者提供了一種重要的緩解疾病治療選擇。隨著醫療機構優先考慮治療方法，這種臨床轉變正在推動顯著的商業性成長。特別是，百時美施貴寶公司在其2025年10月發布的2025年第三季財報中指出，受血液疾病領域強勁需求的推動，Reblozyl®的全球銷售額達到6.15億美元，年成長31%。

同時，口服丙酮酸激酶活化劑的問世，也標誌著為各種地中海貧血基因型患者提供便利、非侵入性治療方法的重大進展。這一趨勢標誌著治療方式從複雜的注射療法轉向小分子干涉，這些小分子藥物能夠增強細胞代謝、改善血紅蛋白穩定性並減少溶血。這些口服治療方法的出現滿足了α-地中海貧血和BETA-地中海貧血患者居家管理的一項重大未滿足需求。作為此發展趨勢的佐證，美國FDA於2025年12月核准了First-in-Class口服活化劑mitapivat上市。 Agios Pharmaceuticals在題為「FDA核准Agios的AQVESME」的新聞稿中宣布了這一消息，為輸血依賴型和非輸血依賴型地中海型貧血成人患者確立了新的治療標準。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球地中海貧血治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（鐵螯合劑、輸血、紅系成熟促進劑、幹細胞療法等）
    • 依類型（α地中海貧血、BETA地中海貧血）
    • 依最終用戶（醫院、研究機構等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美地中海貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲地中海貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區地中海貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲地中海貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲地中海貧血治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球地中海貧血治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bluebird Bio, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • ApoPharma Inc.
  • Pfizer, Inc.
  • Celgene Corporation
  • Takeda Pharmaceuticals Company Limited
  • Incyte Corporation
  • Bellicum Pharmaceuticals
  • GSK plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15590

The Global Thalassemia Treatment Market is projected to expand from USD 923.81 Million in 2025 to USD 1456.22 Million by 2031, registering a CAGR of 7.88%. Treatment modalities encompassed within this sector include chronic blood transfusions, iron chelation therapies, bone marrow transplants, and emerging gene therapies. Growth is largely propelled by the increasing global incidence of genetic blood disorders and the integration of curative interventions like gene editing technologies. Additionally, the market is being bolstered by the broadening of government-backed screening initiatives and the regulatory approval of innovative therapeutic agents, alongside strong pipeline developments aiming to lower transfusion dependency in beta-thalassemia patients.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 923.81 Million
Market Size 2031USD 1456.22 Million
CAGR 2026-20317.88%
Fastest Growing SegmentAlpha Thalassemia
Largest MarketNorth America

Despite this progress, widespread adoption is hindered by the exorbitant costs of new therapies and the logistical complexities associated with chronic transfusion protocols. Securing a consistent and safe blood supply remains a major operational challenge in numerous regions. For instance, the Thalassemia International Federation noted that in 2025, over 75 percent of patients in low- and middle-income nations faced blood insufficiency. Such disparities in resource availability continue to create significant hurdles for market accessibility and the equitable distribution of treatments on a global scale.

Market Driver

The commercialization of curative gene editing therapies is fundamentally transforming the Global Thalassemia Treatment Market by shifting the focus from chronic management to potential functional cures. This evolution is driven by the approval and deployment of high-value ex vivo gene therapies targeting the genetic roots of transfusion-dependent beta-thalassemia, which are securing significant market value and traction in specialized centers. For example, in its "Third Quarter 2024 Results" from November 2024, Bluebird Bio reported 57 patient starts across its commercial portfolio year-to-date, with 35 attributed to the beta-thalassemia therapy Zynteglo. Reinforcing this financial maturation, Vertex Pharmaceuticals announced in its "Q3 2024 Financial Results" in November 2024 that it had generated its first commercial revenue of $2 million from the gene editing therapy Casgevy.

Concurrently, the increasing global prevalence of thalassemia and hemoglobinopathies maintains strong demand for both innovative therapeutics and supportive care regimens. As diagnostic capabilities enhance and demographics shift, the patient population requiring lifelong care is growing, especially in regions with high concentrations of genetic traits. According to the "Global Map of Evidence and Gaps" review released by the Thalassemia International Federation in January 2025, roughly 300,000 children are born annually with hemoglobinopathies worldwide, highlighting the urgent need for scalable treatments. This expanding disease burden necessitates substantial healthcare investment, ensuring that while gene therapies occupy the premium market segment, the foundational demand for iron chelation and transfusion infrastructure remains a crucial volume driver.

Market Challenge

The prohibitive costs associated with novel gene therapies constitute a major restraint on the growth of the Global Thalassemia Treatment Market. While these advanced interventions offer curative possibilities, their pricing structures impose severe financial strain on healthcare payers and reimbursement frameworks. This economic pressure limits widespread adoption, as numerous private insurers and public health programs find it difficult to manage the substantial upfront expenditures these treatments require. As a result, the disparity between regulatory approval and actual patient access is widening, restricting revenue potential for manufacturers across both emerging and established markets.

This financial exclusivity creates significant barriers to equitable access, as evidenced by current industry pricing. The Thalassemia International Federation reported in 2025 that the average acquisition cost for a single administration of an approved gene editing therapy exceeded USD 2.1 million per patient. Such a pricing barrier effectively precludes a large portion of the target population from obtaining curative care, thereby slowing the market's overall growth trajectory and limiting lucrative commercial opportunities to a narrow demographic within wealthy or heavily subsidized healthcare systems.

Market Trends

The market is being reshaped by the increasing adoption of erythroid maturation agents, which address ineffective erythropoiesis to significantly lower transfusion dependency. These biologic therapies target the late stages of red blood cell differentiation, providing a vital disease-modifying option for patients who are unable to access or are ineligible for curative gene editing. This clinical shift is driving substantial commercial growth as providers prioritize treatments that reduce the logistical demands of chronic transfusions; notably, Bristol Myers Squibb reported in its "Third Quarter 2025 Financial Results" in October 2025 that global revenues for Reblozyl rose 31 percent year-over-year to $615 million, fueled by robust demand in hematology.

In parallel, the introduction of oral pyruvate kinase activators signifies a key advancement in providing accessible, non-invasive therapies for various thalassemia genotypes. This trend moves away from complex injectable regimens toward small-molecule interventions that boost cellular metabolism to enhance hemoglobin stability and decrease hemolysis. The availability of these oral options fulfills a significant unmet need for convenient, home-based management for both alpha- and beta-thalassemia patients. A testament to this evolution occurred in December 2025, when Agios Pharmaceuticals announced in the press release "FDA Approves Agios' AQVESME" that the U.S. FDA had approved mitapivat, the first-in-class oral activator, setting a new therapeutic standard for adults with transfusion-dependent and non-transfusion-dependent thalassemia.

Key Market Players

  • Bluebird Bio, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • ApoPharma Inc.
  • Pfizer, Inc.
  • Celgene Corporation
  • Takeda Pharmaceuticals Company Limited
  • Incyte Corporation
  • Bellicum Pharmaceuticals
  • GSK plc

Report Scope

In this report, the Global Thalassemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Thalassemia Treatment Market, By Treatment

  • Iron Chelating Drugs
  • Blood Transfusions
  • Erythyroid Maturation Agents
  • Stem Cell Therapy
  • Others

Thalassemia Treatment Market, By Type

  • Alpha Thalassemia
  • Beta Thalassemia

Thalassemia Treatment Market, By End User

  • Hospitals
  • Research Institutes
  • Others

Thalassemia Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Thalassemia Treatment Market.

Available Customizations:

Global Thalassemia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Thalassemia Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Iron Chelating Drugs, Blood Transfusions, Erythyroid Maturation Agents, Stem Cell Therapy, Others)
    • 5.2.2. By Type (Alpha Thalassemia, Beta Thalassemia)
    • 5.2.3. By End User (Hospitals, Research Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Thalassemia Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Thalassemia Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Thalassemia Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Thalassemia Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End User

7. Europe Thalassemia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Thalassemia Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. France Thalassemia Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Thalassemia Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Thalassemia Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Thalassemia Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End User

8. Asia Pacific Thalassemia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Thalassemia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Thalassemia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Thalassemia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Thalassemia Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Thalassemia Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. Middle East & Africa Thalassemia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Thalassemia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Thalassemia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Thalassemia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User

10. South America Thalassemia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Thalassemia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Thalassemia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Thalassemia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Thalassemia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bluebird Bio, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. Novartis AG
  • 15.4. ApoPharma Inc.
  • 15.5. Pfizer, Inc.
  • 15.6. Celgene Corporation
  • 15.7. Takeda Pharmaceuticals Company Limited
  • 15.8. Incyte Corporation
  • 15.9. Bellicum Pharmaceuticals
  • 15.10. GSK plc

16. Strategic Recommendations

17. About Us & Disclaimer